Skip to Main Content

National Coverage Analysis (NCA) for Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (CAG-00422N)

Expand/collapse the Contacts section

Contact(s)

Lori Paserchia, MD

Leslye Fitterman, PhD

Leslye.fitterman3@cms.hhs.gov

410-786-1806

Back to Top

Expand/collapse the Documents section

Documents

Tracking Sheet

Technology Assessment for Outcomes of Sipuleucel-T Therapy

Proposed Decision Memo

Decision Memo

View Public Comments

NCD for Autologous Cellular Immunotherapy Treatment (110.22)

MEDCAC Meeting for On Label and Off-Label Use of Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer

Back to Top

Expand/collapse the History of Considerations section

History of Considerations

Original Consideration for Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (this document)

Back to Top

Footer Links

www